Lys43
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys43  -  AML1 (human)

Site Information
AGAALAGkLRSGDRs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 459072
Available spectra:  3 CST

In vivo Characterization
Methods used to characterize site in vivo:
3H acetate labeling ( 14 ) , [14C] acetate labeling ( 14 ) , immunoprecipitation ( 14 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 11 , 12 , 13 ) , mutation of modification site ( 14 ) , western blotting ( 14 )
Disease tissue studied:
gastric cancer ( 6 ) , leukemia ( 12 , 14 ) , T cell leukemia ( 14 ) , lung cancer ( 1 , 2 , 3 ) , non-small cell lung cancer ( 1 , 2 , 3 , 5 , 7 ) , non-small cell lung adenocarcinoma ( 1 , 2 , 3 ) , non-small cell large cell lung carcinoma ( 1 , 3 )
Relevant cell line - cell type - tissue:
3T3 (fibroblast) ( 14 ) , Cal-12T (pulmonary) ( 2 ) , COS7 (fibroblast) ( 14 ) , HCC44 (pulmonary) ( 2 ) , HCC78 (pulmonary) ( 1 ) , HEK293T (epithelial) ( 14 ) , HeLa (cervical) ( 14 ) , Jurkat (T lymphocyte) ( 4 , 9 ) , lung ( 1 , 2 , 3 ) , M1 (myeloid) ( 14 ) , MKN-45 (gastric) ( 6 ) , MOLT-4 (T lymphocyte) ( 14 ) , MV4-11 (macrophage) ( 9 , 10 ) , NCI-H1299 (pulmonary) ( 3 ) , NCI-H1437 (pulmonary) ( 2 ) , NCI-H1666 (pulmonary) ( 2 ) , NCI-H1734 (pulmonary) ( 3 ) , NCI-H1781 (pulmonary) ( 1 ) , NCI-H1944 (pulmonary) ( 3 ) , NCI-H2228 (pulmonary) ( 1 ) , NCI-H2405 (pulmonary) ( 2 ) , NCI-H3122 (pulmonary) ( 1 , 5 ) , NCI-H3255 (pulmonary) ( 7 ) , NCI-H358 (pulmonary) ( 3 ) , NCI-H460 (pulmonary) ( 3 ) , NCI-H661 (pulmonary) ( 1 ) , OCI-ly3 (B lymphocyte) ( 11 ) , OCI/AML2 (myeloid) ( 12 , 13 )

Upstream Regulation
Treatments:
vorinostat ( 9 )

Downstream Regulation
Effects of modification on AML1:
molecular association, regulation ( 14 )
Effects of modification on biological processes:
cell growth, induced ( 14 ) , transcription, induced ( 14 )
Induce interaction with:
DNA ( 14 )

References 

1

Rikova K (2013) CST Curation Set: 20219; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

2

Rikova K (2013) CST Curation Set: 20220; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

3

Rikova K (2013) CST Curation Set: 20216; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

4

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

5

Rikova K (2013) CST Curation Set: 18855; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

6

Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

7

Rikova K (2012) CST Curation Set: 16031; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

8

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

9

Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40
19608861   Curated Info

10

Cherry J (2007) CST Curation Set: 2475; Year: 2007; Biosample/Treatment: cell line, MV4-11/DMSO; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

11

Cherry J (2007) CST Curation Set: 2437; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

12

Gu T (2005) CST Curation Set: 1005; Year: 2005; Biosample/Treatment: cell line, OCI/AML2/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

13

Gu T (2005) CST Curation Set: 957; Year: 2005; Biosample/Treatment: cell line, OCI/AML2/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

14

Yamaguchi Y, et al. (2004) AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. J Biol Chem 279, 15630-8
14752096   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.